Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX ) and Takeda (TSE:4502/NYSE:TAK ) today announced positive ...

More participants in the higher-dose group than placebo achieved an HbA1c under 7% (55.9% vs 15.2%) or under 6.5% (29.4% vs 6 ...

Rusfertide met all primary and secondary endpoints in a Phase 3 trial for polycythemia vera, with strong efficacy and safety ...

Among phlebotomy-dependent patients with polycythemia vera, the addition of rusfertide to standard-of-care treatment resulted ...

"Receiving orphan drug designation from the FDA is a significant milestone for DiagnaMed and validates the promise of molecular hydrogen as a potential treatment for ALS. We are excited to partner ...

In addition to the patent, Revive also gets the intellectual and work property derived from DiagnaMed’s research activities ...

TORONTO, March 3, 2025 – Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of ...

Multiple system atrophy (MSA) is not exactly a household word – a situation that Alterity Therapeutics is seeking to change.

Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) today announced positive topline results for the Phase 3 V ...

Namodenoson is currently being evaluated in Liveration TM, a pivotal Phase III study for advanced liver cancer that has been approved by both the U.S. Food and Drug Administration (FDA) and the ...

Argenx had cash, cash equivalents, and other short-term investments totaling $3.4 billion as of the end of 2024, making it well-positioned to continue funding its pipeline and commercialization ...

Several rare disease patient populations received their first-ever FDA-approved drug since Rare Disease Day last year, ...